Abstract | PURPOSE OF REVIEW: RECENT FINDINGS: We first describe the biochemistry of apoC-II and its role in TRL metabolism. We then review the clinical findings of HTG, particularly those related to apoC-II deficiency, and how TG metabolism relates to the development of atherosclerosis. We next summarize the current efforts to develop new drugs for HTG. Finally, we describe recent efforts to make small synthetic apoC-II mimetic peptides for activation of LPL and how these peptides unexpectedly have other mechanisms of action mostly related to the antagonism of the TG-raising effects of apoC-III. SUMMARY: The role of apoC-II in TG metabolism is reviewed, as well as recent efforts to develop apoC-II mimetic peptides into a novel therapy for HTG.
|
Authors | Anna Wolska, Mart Reimund, Alan T Remaley |
Journal | Current opinion in lipidology
(Curr Opin Lipidol)
Vol. 31
Issue 3
Pg. 147-153
(06 2020)
ISSN: 1473-6535 [Electronic] England |
PMID | 32332429
(Publication Type: Journal Article, Research Support, N.I.H., Intramural, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Apolipoprotein C-II
- Apolipoprotein C-III
- Lipoproteins
- Lipoproteins, HDL
- Peptides
- Triglycerides
- apolipoprotein C-II (St Michael)
- lipoprotein triglyceride
- Lipoprotein Lipase
|
Topics |
- Apolipoprotein C-II
(genetics)
- Apolipoprotein C-III
(genetics)
- Atherosclerosis
(drug therapy, genetics, pathology)
- Humans
- Hypertriglyceridemia
(drug therapy, genetics, pathology)
- Lipoprotein Lipase
(genetics)
- Lipoproteins
- Lipoproteins, HDL
(genetics)
- Peptides
(therapeutic use)
- Triglycerides
(genetics, metabolism)
|